Argus Research Maintains Buy on MongoDB, Raises Price Target to $550

Argus Research analyst Joseph Bonner maintains MongoDB (NASDAQ:MDB) with a Buy and raises the price target from $406 to $550.

byvishwanath@benzinga.com

September 7, 2021

1 minute read

Argus Research analyst Joseph Bonner maintains MongoDB (NASDAQ:MDB) with a Buy and raises the price target from $406 to $550.

Analyst Ratings

What 5 Analyst Ratings Have To Say About Home Point Capital

By Benzinga Insights

Today, 5:03 AM

Analysts have provided the following ratings for Home Point Capital (NASDAQ:HMPT) within the last quarter:

HMPT

FDA
News

Heron Therapeutics Announces Filing Of An Efficacy Supplement For Zynrelef

By Benzinga Newsdesk

Today, 5:03 AM

- Supplemental New Drug Application Submitted Requesting Expansion of Indication to Broadly Cover Soft Tissue and Orthopedic Surgical Procedures - - Omnibus Spending Bill (H.R. 2617) Includes Provision to Provide

HRTX

Biohaven Pharmaceutical Q3 EPS $(1.91) Beats $(2.40) Estimate, Sales $135.74M Beat $128.40M Estimate

By Benzinga Newsdesk

Today, 5:03 AM

Biohaven Pharmaceutical (NYSE:BHVN) reported quarterly losses of $(1.91) per share which beat the analyst consensus estimate of $(2.40) by 20.42 percent. This is a 28.46 percent increase over losses of $(2.67) per share

BHVN

FDA
News

Novavax Announces Initiation Of Phase 2b/3 Hummingbird Global Clinical Trial For Novavax COVID-19 Vaccine In Children Aged Six Months Through 11 Years

By Benzinga Newsdesk

Today, 5:03 AM

Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of its Phase 2b/3

NVAX

Argus Research Maintains Buy on MongoDB, Raises Price Target to $550

Related Posts

What 5 Analyst Ratings Have To Say About Home Point Capital

Heron Therapeutics Announces Filing Of An Efficacy Supplement For Zynrelef

Biohaven Pharmaceutical Q3 EPS $(1.91) Beats $(2.40) Estimate, Sales $135.74M Beat $128.40M Estimate

Novavax Announces Initiation Of Phase 2b/3 Hummingbird Global Clinical Trial For Novavax COVID-19 Vaccine In Children Aged Six Months Through 11 Years